13F Portfolios

Dorsey Asset Management, LLC: ROYALTY PHARMA PLC (RPRX): Quarterly 13F Position History

As of Q1 2026, Dorsey Asset Management, LLC reported 2,276,570 shares of ROYALTY PHARMA PLC (RPRX), worth $109.2M and representing 8.7% of its 13F equity book. Quarter-over-quarter share count change: + 17,101 (+0.8%) . The position first appeared in Q3 2025 and has been disclosed across 3 13F-HR filings in Pactolio's tracked window.

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 3 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q1 2026 2,276,570 +17,101 +0.8% $109.2M 8.7% $48.0
Q4 2025 2,259,469 90,980 -3.9% $87.3M 7.6% $38.6
Q3 2025 2,350,449 $82.9M 7.5% $35.3

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.

When did Dorsey Asset Management, LLC first disclose a RPRX position in 13F-HR filings?

Dorsey Asset Management, LLC first reported ROYALTY PHARMA PLC (RPRX) on its 13F-HR filing for the period ending 2025-09-30 (Q3 2025). The position has appeared on 3 reported quarters within Pactolio's tracked window.

What was Dorsey Asset Management, LLC's most recent quarter-over-quarter share-count change in RPRX?

Between Q4 2025 and Q1 2026, Dorsey Asset Management, LLC added 17,101 shares of RPRX (+0.8%), bringing the total reported position to 2,276,570 shares at a market value of $109.2M.

Does the implied price-per-share represent Dorsey Asset Management, LLC's cost basis in RPRX?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.